---
title: "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289514280.md"
description: "Travere Therapeutics announced inducement equity grants under Nasdaq Listing Rule 5635(c)(4). On June 10, 2026, the Compensation Committee granted restricted stock units (RSUs) covering 32,000 shares to six new employees. These RSUs vest over four years and were granted outside the 2018 Equity Incentive Plan as material inducements for new hires."
datetime: "2026-06-11T13:00:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289514280.md)
  - [en](https://longbridge.com/en/news/289514280.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289514280.md)
---

# Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable vesting dates.

**About Travere Therapeutics**

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260611847737/en/

Media:  
888-969-7879  
mediarelations@travere.com

Investors:  
888-969-7879  
IR@travere.com

Source: Travere Therapeutics, Inc.

### Related Stocks

- [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md)

## Related News & Research

- [Travere Therapeutics (NASDAQ:TVTX) Posts Quarterly Earnings Results, Beats Estimates By $999.24 EPS](https://longbridge.com/en/news/285114233.md)
- [Travere Therapeutics (NASDAQ:TVTX) Insider Sells $13,668.45 in Stock](https://longbridge.com/en/news/285472720.md)
- [Is Dover Stock Underperforming the Nasdaq?](https://longbridge.com/en/news/289608765.md)
- [Is Cencora Stock Underperforming the Nasdaq?](https://longbridge.com/en/news/289067663.md)
- [Assessing Zoom Communications (NasdaqGS:ZM) Valuation After Recent Name Change And Share Price Pullback](https://longbridge.com/en/news/289531751.md)